A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects with Relapsed or Refractory Multiple Myeloma.

Trial Profile

A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects with Relapsed or Refractory Multiple Myeloma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs Daratumumab (Primary) ; JNJ 63723283 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2018 Planned primary completion date changed from 15 Mar 2018 to 31 Mar 2019.
    • 26 May 2018 Status changed from recruiting to discontinued, as reported in the Genmab media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top